Aurobindo Pharma gains as its arm to acquire 100% membership interest in Lannett Company LLC
Aurobindo Pharma is currently trading at Rs 1164.60, up by 7.60 points or 0.66% from its previous closing of Rs 1157.00 on the BSE.
The scrip opened at Rs 1136.35 and has touched a high and low of Rs 1171.85 and Rs 1136.35 respectively. So far 24147 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1592.55 on 13-Sep-2024 and a 52-week low of Rs 994.35 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 1171.85 and Rs 1107.65 respectively. The current market cap of the company is Rs 67422.36 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.30% and 6.87% respectively.
Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc has entered into a definitive agreement with Lannett Seller Holdco, Inc under which Aurobindo Pharma USA Inc will acquire 100% of membership interest in Lannett Company LLC from Lannett Seller Holdco, Inc.
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities. Through this acquisition, Aurobindo will gain access to a complementary portfolio of profitable products, growing Contract Development and Manufacturing Organization (CDMO) business and U.S.-based manufacturing facility with significant excess capacity (425k sq ft facility with around 3.6 billion doses capacity) and with potential for further expansion.
The acquired product portfolio is primarily focused on non-opioid controlled substances, particularly in ADHD therapeutics for which Aurobindo currently has a limited presence. This acquisition strengthens Aurobindo’s ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
